News about "Novo Nordisk"

Novo Nordisk Higher-Dose Wegovy Shows 28 Percent Weight Loss in Early Responders

Novo Nordisk reports new analyses showing higher-dose Wegovy helped early responders achieve up to 28 percent weight loss, highlighting its effectiveness for obesity treatment regardless of response speed.

Novo Nordisk | 13/05/2026 | By News Bureau

Novo Nordisk Wins FDA Approval for Wegovy HD to Advance Obesity Treatment

FDA approves Novo Nordisk’s Wegovy HD (semaglutide 7.2 mg), a higher-dose weekly injection delivering significant weight loss, supported by strong Phase III trial outcomes.

Novo Nordisk | 21/03/2026 | By News Bureau |  127

FDA Clears Novo Nordisk's Sogroya for Three New Paediatric Uses

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Sogroya for three additional paediatric indications, expanding its use in children aged 2.5 years and older and reinforcing its position as the only once-weekly, long-acting growth hormone with the broadest approved label.

Novo Nordisk | 02/03/2026 | By News Bureau |  143

Novo Nordisk Signs USD 2.1 Billion Pact with Vivtex to Develop Oral Obesity Therapies

Novo Nordisk has entered into a strategic collaboration with US-based Vivtex to develop next-generation oral biologic therapies for obesity, diabetes and related metabolic conditions.

Novo Nordisk | 27/02/2026 | By Darshana |  124

Novo Nordisk Plans Wegovy Vial Launch to Expand Obesity Care Options

Danish drugmaker Novo Nordisk is planning to introduce vial presentations of its blockbuster obesity treatment Wegovy (semaglutide), expanding the range of delivery formats available for the therapy as competition intensifies in the weight-management market.

Novo Nordisk | 12/02/2026 | By Darshana |  180

Novo Nordisk Introduces Wegovy Pill with knownwell as NovoCare Provider

Novo Nordisk has launched Wegovy in an oral pill form, marking the first FDA-approved oral GLP-1 therapy, with knownwell recognised as a NovoCare provider to support broader patient access to clinician-led metabolic care across the US.

Novo Nordisk | 06/01/2026 | By News Bureau |  137

US FDA Approves Wegovy by Novo Nordisk as first Oral GLP-1 for Weight Loss

Wegovy’s approval is supported by phase III OASIS 4 trial data showing a mean weight loss of 16.6 percent, with the oral GLP-1 indicated for long-term weight management and reduction of major adverse cardiovascular events, and Novo Nordisk planning a US launch in early January 2026.

Novo Nordisk | 23/12/2025 | By News Bureau |  280

Emcure Launches Poviztra to Broaden Access to Weight Management Therapy

Emcure has launched Poviztra, a once-weekly weight management therapy available in a pen device across five dosage strengths, with prices starting at INR 8,790 per month, aimed at improving access through convenient and precise dosing.

Novo Nordisk | 22/12/2025 | By News Bureau |  305

Takeda Becomes a BaseLaunch Partner

BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.

Novo Nordisk | 19/12/2025 | By News Bureau |  120

Novo Nordisk Seeks FDA Approval for CagriSema Weight-Loss Therapy

CagriSema 2.4 mg/2.4 mg is an investigational once-weekly injectable combining cagrilintide and semaglutide to target complementary obesity pathways. In the REDEFINE 1 phase III trial, patients with obesity or overweight achieved an average weight loss of 23 percent, reinforcing the company’s ongoing focus on innovation in obesity treatment.

Novo Nordisk | 19/12/2025 | By News Bureau |  219